Key points are not available for this paper at this time.
Effect of ticlopidine administration, a new inhibitor of platelet aggregation, at daily dose of 300mg was compared with aspirin at daily dose of 500mg in double blind basis. The suppression of platelet aggregations induced with ADP, collagen and epinephrine were compared in 38 cases of thrombotic tendency or enhanced platelet functions.Overall judgement of the inhibitory efficacy of ticlopidine on the aggregations induced with collagen or epinephrine was shown to be as potent as that of aspirin, but the inhibitory efficacy of ticlopidine on the aggregation induced with ADP was apparently superior to that of aspirin. The maximum aggregation rate was significantly decreased and aggregation profile was improved in the ticlopidine-treated group when compared with the aspirin-group. Maximum aggregation rates induced with collagen or epinephrine were significantly decreased in both groups to the same extent.Blood filtration velocity through Nuclepore filter of 5μm pore size was significantly enhanced in the ticlopidine-group but not in the aspirin-group. Other coagulation parameters and laboratory data were unchanged in both groups, except bleeding time and prothrombin time which were slightly prolonged in the aspirin group.From above results, it was expected that ticlopidine may exert superior clinical effect to aspirin on thrombotic diseases and microcirculatory disorders.
Abe et al. (1980) studied this question.